Free Trial

Leerink Partnrs' Rating of LENZ Therapeutics on 4/15/2024

On April 15, 2024, Leerink Partnrs updated its outlook on LENZ Therapeutics (NASDAQ:LENZ) with the action "Reiterated Rating", keeping a "Outperform" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.